AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04553380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basic insulin
Description: 1. Initial dose of basic insulin: 0.2U/kg/d.~2. Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~3. Injection time: subcutaneous injection before going to bed every night.
Study NCT04553380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basic insulin
Description: 1. Initial dose of basic insulin: 0.2U/kg/d.~2. Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~3. Injection time: subcutaneous injection before going to bed every night.
Study NCT03723304 — intervention group
Intervention type: PROCEDURE
Intervention: Bridging followed by transplant
Description: Trans-arterial chemoembolization or percutaneous alcohol injection or radio-frequency ablation during the waiting time followed by liver transplant
Study NCT03723304 — intervention group
Intervention type: PROCEDURE
Intervention: Direct liver transplant
Description: Direct liver transplant (no neoadjuvant approaches during the waiting time period)
Study NCT05446818 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa flavanol (CF)
Description: 2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)
Study NCT05446818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (P)
Description: 2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)
Study NCT01264705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab (0.3 mg/kg) and sorafenib
Description: Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
Study NCT01264705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab (1.0 mg/kg ) and sorafenib
Description: Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
Study NCT01264705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab (3.0 mg/kg) and sorafenib
Description: Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
Study NCT03924167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weaving Healthy Families Program
Description: The Weaving Healthy Families program is created from integrating the widely disseminated, ecological, innovative, and culturally grounded Framework of Historical Oppression, Resilience, and Transcendence (FHORT) with the the Celebrating Families! evidenced-based program (EBP). The goal of this program is to reduce and postpone Alcohol and other Drug (AOD) use, decrease and prevent violence in families, and promote resilience and wellness (including mental health) among NA adults and youth. This intervention seeks to promote wellness by targeting key behavioral (AOD), mental/emotional (emotional regulation/anger management, cognitions, resilience), social and familial (healthy and safe relationships, the family environment, and parenting), cultural (values, traditions), and physical (nutrition) factors.
Study NCT01124006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradiscal rhGDF-5
Description: The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
Study NCT01124006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection
Description: Sterile water for injection
Study NCT03518255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature video
Description: After signing the Informed Consent Form, the participants will respond to a demographic questionnaire to characterize the sample and then they will watch nature videos. After that, will be applied a scale questionnaire about the physical and psychological symptoms of chemotherapy in the positive and negative mood of that patient.
Study NCT03679507 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Ultrasound Therapy
Description: Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.
Study NCT03679507 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Low Intensity Ultrasound Therapy
Description: Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.
Study NCT03679507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhancing CBD oil penetration into joints by sonophresis
Description: High CBD oil will be applied to the affected knee of one-half of the recruited subjects.
Study NCT01600144 — intervention group
Intervention type: OTHER
Intervention: digital mammography
Description: data collection
Study NCT00500435 — intervention group
Intervention type: PROCEDURE
Intervention: Extraperitoneal Laparoscopic Lymphadenectomy
Description: Laparoscope used to find and remove para aortic lymph nodes in abdomen.
Study NCT02840799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate (KNO3)
Description: The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.
Study NCT02840799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Chloride (KCl)
Description: Potassium Chloride (KCl) is the matching placebo control drug in this trial.
Study NCT03485872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Screening and Referral Information
Description: Urinary incontinence self-screening questionnaire, fact sheet and self-referral information will be provided by mail or email.
Study NCT03485872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Demographic and quality of life questionnaires; standard care provided by participants' GPs
Study NCT03296319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Echocardiography guided fluid administration
Study NCT03296319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Echocardiography guided fluid administration
Study NCT00959985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Sleeve
Description: Worn for a minimum of 12 hours per day
Study NCT00959985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short-Stretch Compression Bandage
Description: Worn overnight at least 5 nights of the week
Study NCT01712399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg
Description: Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years
Study NCT04112485 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microdiscectomy
Study NCT03622866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-high pulse width stimulation
Description: Algovita Spinal Cord Stimulation System with associated components
Study NCT03622866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional pulse width stimulation
Description: Algovita Spinal Cord Stimulation System with associated components
Study NCT02655237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix tablets
Study NCT02655237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relugolix Placebo
Description: Relugolix placebo-matching tablets
Study NCT02655237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix Placebo
Description: Relugolix placebo-matching tablets
Study NCT02655237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin
Description: Leuprorelin injection
Study NCT02655237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin Placebo
Description: Leuprorelin placebo-matching injections
Study NCT02655237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin Placebo
Description: Leuprorelin placebo-matching injections
Study NCT02572310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplex High Viscosity Bone Cement
Description: high viscosity bone cement for total knee replacement
Study NCT02580630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduction in running and jumping
Description: Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.
Study NCT02580630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.
Study NCT02580630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided injection with Glucocorticosteroid
Description: Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
Study NCT02580630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided injection with local anaestethic
Description: Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
Study NCT03230851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 100mg/d therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/d
Study NCT03230851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 100mg/2d therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/2d
Study NCT03230851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 100mg/3d therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/3d
Study NCT03230851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 50mg bid therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 50mg bid
Study NCT03230851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 75mg/d therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 75mg/d
Study NCT03230851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 50mg/d therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 50mg/d
Study NCT03230851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indobufen 100mg bid therapy
Description: 100mg aspirin for at least 5 days followed by indobufen 100mg bid
Study NCT00918567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: open label treatment dosed up to 1.8mg/kg/day
Study NCT00918567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atomoxetine
Description: open label treatment dosed up to 1.8mg/kg/day
Study NCT00918567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Modification Therapy
Description: 8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
Study NCT01173770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680B
Description: Escalating single doses ADC3680B or Placebo over 5 study periods
Study NCT01173770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680B
Description: ADC3680B or Placebo for 7 days
Study NCT01173770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680B
Description: Single doses ADC3680B over 2 study periods under fasted and fed conditions
Study NCT02126865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 1060469
Description: tablet
Study NCT02126865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469 Healthy
Description: tablet
Study NCT02126865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 1060469 asthmatics
Description: tablet
Study NCT02126865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469 asthmatics
Description: tablet
Study NCT01437865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadofosveset contrast agent enhanced MRI Axilla
Description: A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
Study NCT01714648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.2 mg
Description: A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.
Study NCT01887626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg whole tablet
Description: Ticagrelor 90 mg whole tablet administered as a single oral dose
Study NCT01887626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg tablet crushed
Description: Ticagrelor 90 mg crushed and suspended in water
Study NCT01887626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube
Description: Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
Study NCT05531409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsible Behavior for Younger Children (RBYC)
Description: RBYC is a school-based universal prevention program designed to provide adolescents and their parents (or other guardians) with the knowledge and tools to help adolescents interact appropriately with younger children and avoid engaging younger children in sexual behaviors.
Study NCT00263809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pathogen Reduction Technology
Study NCT00003313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003313 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Study NCT00003313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Study NCT00003313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00003313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Study NCT00003313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00003313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Study NCT00003313 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00003313 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT00429806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA
Study NCT00429806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02451605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic nerve blockade (Ropivacaine)
Description: Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.
Study NCT02451605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement surgery.
Description: Total knee replacement surgery.
Study NCT03286582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-203 1% Topical Ointment
Description: AC-203 1% ointment BID (twice daily)
Study NCT03286582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol 0.05% Topical Ointment
Description: Clobetasol 0.05% Topical Ointment BID
Study NCT01179919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Capsule, 75 mg by mouth for 9 doses
Study NCT00169195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
Study NCT01507857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 400U /0.5ml EV71 vaccine
Description: inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
Study NCT01507857 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, 28 days interval
Study NCT03202836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: vaginal utrogestan
Study NCT03202836 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tocolytics
Description: tocolysis for 48 hours
Study NCT03202836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocolytics
Description: tocolysis for 48 hours
Study NCT03202836 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Steroids
Description: antenatal corticosteroids for 48 hours
Study NCT03202836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: antenatal corticosteroids for 48 hours
Study NCT02879019 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stretching exercise group
Description: In each stretching class, approximately 20 exercises will be performed. The total duration of the session will be approximately 30 minutes.
Study NCT02879019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking training group
Description: Patients will perform two walking session per week, each consisting of 15\*2-min walking bouts, with 2-min of rest in between. The intensity will be set at heart rate corresponding to the pain threshold.
Study NCT01089647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide and montelukast
Description: budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
Study NCT01089647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
Study NCT04567342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 automated message
Description: Parents of eligible patients will receive 1 HIPAA compliant automated call or text reminder (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
Study NCT04567342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 automated messages
Description: Parents of eligible patients will receive 2 HIPAA compliant automated call or text reminders (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
Study NCT04567342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No personal contact attempt
Description: No personal contact attempts will be made.
Study NCT04567342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 personal contact attempt
Description: Parents of eligible patients will receive a text from a medical assistant informing them that their child is due for a check up. This will be followed by personal call from the medical assistant to assist the parent with scheduling an appointment.
Study NCT04598243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smart Energy System
Description: A nutritional /herbal combination
Study NCT00076050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Description: Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
Study NCT00076050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo soy isoflavones
Study NCT01025037 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conexa Reconstructive Tissue Matrix
Description: Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
Study NCT01462565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: current marketed FLOLAN (epoprostenol sodium)
Description: continuous intravenous infusion
Study NCT01462565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: new thermo stable formulation of epoprostenol sodium
Description: continuous intravenous infusion